Allakos Faces Strategic Uncertainty Following AK006 Phase 1 Trial Failure and Workforce ...
Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...
Hold Rating on Allakos Amid Clinical and Financial Setbacks with AK006
In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...